Technical analysis of Bone Biologics Corporation (BBLG): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth.
Price Performance
| 1 month | -16.43% |
| 3 months | -63.18% |
| Year-to-date | -62.92% |
| 1 year | -74.52% |
| 3 years | -98.49% |
52-Week Range
| 52-week High | $2.89 |
| 52-week Low | $0.51 |
| Avg Volume (90d) | 284K |
Technical Indicators
| SMA 50 | $0.83 |
| SMA 200 | $1.27 |
| 30-day Volatility (annualised) | 99.8% |
| Price vs SMA 50 | -35.5% |
| Price vs SMA 200 | -57.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.13 | |
| 2025-11 | $1.50 | -29.6% |
| 2025-12 | $1.45 | -3.3% |
| 2026-01 | $1.64 | +13.1% |
| 2026-02 | $1.15 | -29.9% |
| 2026-03 | $1.10 | -4.3% |
| 2026-04 | $1.29 | +17.3% |
| 2026-05 | $1.32 | +2.3% |
| 2026-06 | $1.37 | +3.8% |
| 2026-07 | $0.85 | -38.3% |
| 2026-08 | $0.58 | -31.8% |
| 2026-09 | $0.54 | -6.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $0.54 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.25 |
| EV / EBITDA | 1.38 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 8.67 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -19.57 |